title: Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3.
abstract: Studies have demonstrated that the anti-tumour effect of natural killer (NK) cells is successful for patients with several cancers. Although interleukin-32 (IL-32) is endogenously expressed in NK cells, cytolytic function of NK cells against cancer cells has not been fully demonstrated. In the present study, we found that the growth of cancer cells was suppressed when colon cancer cells or prostate cancer cells were co-cultured with NK-92 cells, an NK cell line. We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells. However, cancer cell growth inhibition and IL-32 expression were abolished when cancer cells were co-cultured with NK cells transfected with small interfering (si) RNA of IL-32. DR3 expression was also diminished by co-culture with IL-32-specific siRNA-transfected NK-92 cells. Expression of APO3L, a ligand of DR3, was elevated in NK cells that were co-cultured with cancer cells. It was also found that expression of apoptosis-related proteins such as cleaved caspase-3 and bax was increased in cancer cells co-cultured with NK-92 cells, but their expression was abolished by co-culture with IL-32 siRNA-transfected NK-92 cells. Moreover, knockdown of DR3 in co-culture of NK-92 cells with cancer cells by siRNA or antibodies of DR3 and APO3L reversed the growth inhibitory effect of NK-92 cells. In conclusion, our study showed that IL-32 enhanced the cytotoxic effect of NK-92 cells on the cancer cells through activation of DR3 and caspase-3.
authors: College of Pharmacy and Medical Research Centre, Chungbuk National University, Cheongju, Korea. pmh5205@hanmail.net
authors: Mi H
authors: MH
authors: Park
authors: Min J
authors: MJ
authors: Song
authors: Min-Chul
authors: MC
authors: Cho
authors: Dong C
authors: DC
authors: Moon
authors: Do Y
authors: DY
authors: Yoon
authors: Sang B
authors: SB
authors: Han
authors: Jin T
authors: JT
authors: Hong
mesh_terms: D053148:Caspase 3 / Q000096:biosynthesis / Q000276:immunology; D045744:Cell Line, Tumor; D018920:Coculture Techniques; D053222:Fas Ligand Protein / Q000096:biosynthesis / Q000276:immunology; D006801:Humans; D007378:Interleukins / Q000037:antagonists & inhibitors / Q000276:immunology*; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology*; D008297:Male; D034741:RNA, Small Interfering / Q000276:immunology / Q000378:metabolism; D053219:Receptors, Tumor Necrosis Factor, Member 25 / Q000096:biosynthesis / Q000276:immunology*; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000276:immunology; D051028:bcl-2-Associated X Protein / Q000096:biosynthesis
chemical_list: C494826:BAX protein, human; D053222:Fas Ligand Protein; C496971:IL32 protein, human; D007378:Interleukins; D034741:RNA, Small Interfering; D053219:Receptors, Tumor Necrosis Factor, Member 25; D047889:Receptors, Tumor Necrosis Factor, Type II; C506033:TNFRSF25 protein, human; D051028:bcl-2-Associated X Protein; D053148:Caspase 3